145 related articles for article (PubMed ID: 29727562)
1. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.
Grasso M; Estrada MA; Berrios KN; Winkler JD; Marmorstein R
J Med Chem; 2018 Jun; 61(11):5034-5046. PubMed ID: 29727562
[TBL] [Abstract][Full Text] [Related]
2. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF
Grasso M; Estrada MA; Ventocilla C; Samanta M; Maksimoska J; Villanueva J; Winkler JD; Marmorstein R
ACS Chem Biol; 2016 Oct; 11(10):2876-2888. PubMed ID: 27571413
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
4. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z
ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962
[TBL] [Abstract][Full Text] [Related]
5.
Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of BRAF dimers using an allosteric site.
Cotto-Rios XM; Agianian B; Gitego N; Zacharioudakis E; Giricz O; Wu Y; Zou Y; Verma A; Poulikakos PI; Gavathiotis E
Nat Commun; 2020 Sep; 11(1):4370. PubMed ID: 32873792
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
[TBL] [Abstract][Full Text] [Related]
8. Development of Highly Sensitive Biosensors of RAF Dimerization in Cells.
Miyamoto K; Sawa M
Sci Rep; 2019 Jan; 9(1):636. PubMed ID: 30679688
[TBL] [Abstract][Full Text] [Related]
9. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib.
Tkacik E; Li K; Gonzalez-Del Pino G; Ha BH; Vinals J; Park E; Beyett TS; Eck MJ
J Biol Chem; 2023 May; 299(5):104634. PubMed ID: 36963492
[TBL] [Abstract][Full Text] [Related]
10. Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors.
Rasmussen DM; Semonis MM; Greene JT; Muretta JM; Thompson AR; Toledo Ramos S; Thomas DD; Pomerantz WCK; Freedman TS; Levinson NM
Elife; 2024 May; 13():. PubMed ID: 38742856
[TBL] [Abstract][Full Text] [Related]
11. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
12. Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.
Tse A; Verkhivker GM
PLoS One; 2016; 11(11):e0166583. PubMed ID: 27861609
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
14. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
Wang L; Zhu G; Zhang Q; Duan C; Zhang Y; Zhang Z; Zhou Y; Lu T; Tang W
Org Biomol Chem; 2017 Apr; 15(16):3455-3465. PubMed ID: 28368067
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.
Verkhivker GM
Mol Biosyst; 2016 Oct; 12(10):3146-65. PubMed ID: 27481329
[TBL] [Abstract][Full Text] [Related]
16. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
17. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
Yao Z; Torres NM; Tao A; Gao Y; Luo L; Li Q; de Stanchina E; Abdel-Wahab O; Solit DB; Poulikakos PI; Rosen N
Cancer Cell; 2015 Sep; 28(3):370-83. PubMed ID: 26343582
[TBL] [Abstract][Full Text] [Related]
18. Path Forward for RAF Therapies: Inhibition of Monomers and Dimers.
Kortum RL; Morrison DK
Cancer Cell; 2015 Sep; 28(3):279-81. PubMed ID: 26373275
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives.
Okaniwa M; Hirose M; Arita T; Yabuki M; Nakamura A; Takagi T; Kawamoto T; Uchiyama N; Sumita A; Tsutsumi S; Tottori T; Inui Y; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
J Med Chem; 2013 Aug; 56(16):6478-94. PubMed ID: 23906342
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
